EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)

被引：0
|
作者：
Petrylak, D. P. [1 ]
Rosenberg, J. [2 ]
Duran, I. [3 ]
Loriot, Y. [4 ]
Sonpavde, G. [5 ]
Wu, C. [6 ]
Gartner, E. [7 ]
Melhem-Bertrandt, A. [8 ]
Powles, T. [9 ]
机构：
[1] Yale Univ, Sch Med, Med Oncol & Urol, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[3] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain
[4] Inst Gustave Roussy, Med Oncol, Paris, France
[5] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[6] Astellas Pharma US Inc, Biostat, Northbrook, IL USA
[7] Seattle Genet Inc, Expt Med, Bothell, WA USA
[8] Astellas Pharma US Inc, Dev Med Sci Oncol, Northbrook, IL USA
[9] Queen Mary Univ London, Barts Canc Inst, London, England
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
922TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] EV-301: Phase Ill study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (Ia/mUC).
    Petrylak, Daniel Peter
    Rosenberg, Jonathan E.
    Duran, Ignacio
    Loriot, Yohann
    Sonpavde, Guru
    Wu, Chunzhang
    Gartner, Elaina M.
    Melhem-Bertrandt, Amal
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
    Matsubara, Nobuaki
    Yonese, Junji
    Kojima, Takahiro
    Azuma, Haruhito
    Matsumoto, Hiroaki
    Powles, Thomas
    Rosenberg, Jonathan E.
    Petrylak, Daniel P.
    Matsangou, Maria
    Wu, Chunzhang
    Campbell, Mary
    Yamashiro, Mayumi
    CANCER MEDICINE, 2023, 12 (03): : 2761 - 2771
  • [3] Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.
    Powles, Thomas
    Rosenberg, Jonathan E.
    Sonpavde, Guru
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Wu Chunzhang
    Campbell, Mary S.
    Matsangou, Maria
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [4] EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
    Petrylak, D. P.
    Rosenberg, J. E.
    Lee, J.
    Yonese, J.
    Duran, I.
    Loriot, Y.
    Sonpavde, G.
    Wu, C.
    Gartner, E. M.
    Melhem-Bertrandt, A.
    Powles, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.
    Mamtani, Ronac
    Rosenberg, Jonathan E.
    Powles, Thomas
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae-Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Sridhar, Srikala S.
    Pappot, Helle
    Valderrama, Begona P.
    Gurney, Howard
    Bedke, Jens
    Van der Heijden, Michiel Simon
    Wu, Chunzhang
    Hepp, Zsolt
    McKay, Caroline
    Petrylak, Daniel P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy
    Gurney, Howard
    Mamtani, Ronac
    Rosenberg, Jonathan E.
    Powles, Thomas
    Sonpavde, Guru P.
    Loriot, Yohann
    Duran, Ignacio
    Lee, Jae Lyun
    Matsubara, Nobuaki
    Vulsteke, Christof
    Castellano, Daniel
    Sridhar, Srikala S.
    Pappot, Helle
    Bedke, Jens
    van der Heijden, Michiel
    Wu Chunzhang
    Hepp, Zsolt
    McKay, Caroline
    Petrylak, Daniel P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 66 - 67
  • [7] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Valderrama, B. Perez
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Gauna, D. E. Castellano
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    van der Heijden, B. M. S. Homet Moreno
    ANNALS OF ONCOLOGY, 2023, 34 : S1340 - S1340
  • [8] EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
    Powles, T. B.
    Perez Valderrama, B.
    Gupta, S.
    Bedke, J.
    Kikuchi, E.
    Hoffman-Censits, J.
    Iyer, G.
    Vulsteke, C.
    Park, S. H.
    Shin, S. J.
    Castellano Gauna, D. E.
    Fornarini, G.
    Li, J-R.
    Gumus, M.
    Mar, N.
    Narayanan, S.
    Yu, X.
    Gorla, S.
    Moreno, B. Homet
    van der Heijden, M. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1557 - S1558
  • [9] Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone, in untreated locally advanced or metastatic urothelial cancer
    van der Heijden, M. S.
    Gupta, S.
    Galsky, M. D.
    Derleth, C.
    Steinberg, J.
    Kataria, R.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2020, 31 : S605 - S606
  • [10] Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
    Rosenberg, J. E.
    Powles, T.
    Sonpavde, G. P.
    Loriot, Y.
    Duran, I.
    Lee, J. L.
    Matsubara, N.
    Vulsteke, C.
    Castellano, D.
    Mamtani, R.
    Sridhar, S. S.
    Pappot, H.
    Gurney, H. P.
    Bedke, J.
    Van der Heijden, M. S.
    Campbell, M.
    Wu, C.
    Matsangou, M.
    Petrylak, D. P.
    ANNALS OF ONCOLOGY, 2021, 32 : S710 - S711
12345